Since the first approval of gemtuzumab ozogamicin (Mylotarg; Pfizer; CD33 targeted), two
additional antibody–drug conjugates (ADC), brentuximab vedotin (Adcetris; Seattle …

Traditional cancer chemotherapy is often accompanied by systemic toxicity to the patient.
Monoclonal antibodies against antigens on cancer cells offer an alternative tumor‐selective …

Purpose: Although extensive-stage small-cell lung cancer (SCLC) is highly responsive to
first-line therapy, virtually all patients develop resistance with short survival. Rovalpituzumab …

The concept of exploiting the specific binding properties of monoclonal antibodies as a
mechanism for selective delivery of cytotoxic agents to tumor cells is an attractive solution to …

A Hybrid drug which comprises the incorporation of two drug pharmacophores in one single
molecule are basically designed to interact with multiple targets or to amplify its effect …

Abstract Introduction Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate
targeting DLL3, an atypical Notch ligand expressed in SCLC tumors. We evaluated the …

Abstract The pyrrolo [2, 1‐c][1, 4] benzodiazepines (PBDs) are a family of sequence‐
selective DNA minor‐groove binding agents that form a covalent aminal bond between their …

Formation of γ-H2AX in response to DNA double stranded breaks (DSBs) provides the basis
for a sensitive assay of DNA damage in human biopsies. The review focuses on the …

DNA double strand breaks (DSB) are the gravest form of DNA damage in eukaryotic cells.
Failure to detect DSB and activate appropriate DNA damage responses can cause genomic …

Upon DNA double-strand break (DSB) induction in mammals, the histone H2A variant,
H2AX, becomes rapidly phosphorylated at serine 139. This modified form, termed γ-H2AX, is …